Kurser indlæses...
Prognose
Analytikernes gennemsnitlige kursmål er 13,65 € (+245,57 %). Medianen er 13,65 € (+245,57 %).
| Køb |
11 |
| Behold |
4 |
| Sælg |
1 |
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Precigen reaches 52-week high at $7.33 after strong quarter
Precigen's stock rose to a 52-week high of $7.33 and has a market capitalization of about $2.62 billion. Over the past year the share price has more than doubled (+100.27%); InvestingPro reports a total return of 123% and a YTD gain of 71%. In the second quarter the company beat expectations with earnings of $0.05 per share (expectation: -$0.01) and revenue of $54.98 million (forecast: $27.83 million), driven by strong demand for PAPZIMEOS; net income was $20.1 million. » Mere på de.investing.com
Precigen beats Q2 forecasts thanks to strong PAPZIMEOS demand
Precigen reported Q2 net income of $20.1 million ($0.05 per share) on revenue of $54.98 million, well above consensus estimates of -$0.01 EPS and $27.83 million in revenue. PAPZIMEOS generated $53.1 million, or 96.4% of revenue; more than 200 patients have received at least one dose and over 100 have completed the full four‑injection treatment. The stock rose 12.56% in after‑hours trading to $7.35 and surpassed its 52‑week high. Management expects continued growth, margin stabilization in the high 80s to low 90s percent range, and cash‑flow breakeven by the end of 2026, but warns of revenue concentration in a single product and existing debt of $100 million. » Mere på de.investing.com
Precigen secures U.S. market exclusivity for PAPZIMEOS until 2032
Precigen holds the first and only FDA-approved therapy for the treatment of recurrent respiratory papillomatosis (RRP) in adults with PAPZIMEOS and has U.S. market exclusivity until 2032. Peak sales potential is over $1 billion, and H.C. Wainwright forecasts more than a doubling of the share price. PAPZIMEOS revenues rose sequentially by more than 535 percent, with growth expected to accelerate further in Q2. The 2028e P/E is stated at 7.4. » Mere på finanzen.net
Precigen secures FDA orphan drug exclusivity for PAPZIMEOS
Precigen won FDA orphan drug exclusivity for PAPZIMEOS, granting seven years of protection that extends market exclusivity through August 2032. PAPZIMEOS, developed with the AdenoVerse platform, targets HPV 6 and 11 to treat adult recurrent respiratory papillomatosis (RRP) and is commercially available in the US. Long-term data presented at ASCO 2026 showed sustained benefit: 83% of complete responders remained surgery-free for at least 36 months and some patients required no interventions beyond four years. » Mere på finance.yahoo.com
Precigen beats Q1 2026 forecasts, stock rises after strong PAPZIMEOS sales
Precigen reported Q1 2026 EPS of $-0.02 (forecast -$0.03) and revenue of $23.25 million, driven by the commercial success of PAPZIMEOS. Operating results improved and the stock rose 10.84% in after-hours trading. Management expects continued revenue growth, reduced cash burn and targets cash‑flow break‑even by the end of 2026, but sees risks from high SG&A costs and dependence on PAPZIMEOS. » Mere på de.investing.com
Virksomhedstal
| (EUR) | september 2026 | YoY |
|---|---|---|
| Omsætning | 65,46 mio. | 2.529,06 % |
| Bruttofortjeneste | 59,72 mio. | 4.366,44 % |
| Nettoresultat | 31,58 mio. | 125,32 % |
| EBITDA | 35,38 mio. | 128,70 % |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 1,4 mia. € |
Antal aktier | 358,55 mio. |
Højeste/laveste i 52 uger | 8,17 € - 2,77 € |
| Udbytte | Nej |
Beta | 0,98 |
P/E (PE Ratio) | 62,81 |
PEG (PEG Ratio) | 0,40 |
K/I (PB Ratio) | 18,34 |
P/S (PS Ratio) | 9,80 |
Virksomhedsprofil
Precigen, Inc. udvikler og udvikler næste generation af gen- og cellulære terapier i USA. Virksomheden leverer også sygdomsmodificerende terapeutika; genetisk modificerede svin til anvendelser inden for regenerativ medicin; og teknologier til reproduktion og embryooverførsel. Derudover tilbyder virksomheden UltraVector-platformen, som anvender avancerede DNA-konstruktionsteknologier og computermodeller til at designe og samle genetiske komponenter til komplekse genekspressionsprogrammer; mbIL15, et gen, der forbedrer de funktionelle egenskaber hos immunceller; Sleeping Beauty, et ikke-virale transposon/transposase-system; AttSite-recombinaser, som bryder og genforbinder DNA ved specifikke sekvenser; AdenoVerse-teknologiplatformen, et bibliotek af konstruerede adenovektor-serotyper; og L. lactis, som er en fødevaregodkendt bakterie. Derudover leverer den RheoSwitch, et induceret genkoblingssystem, der giver kvantitativ, dosisproportional regulering af mængden og timingen af målproteinekspression; kill switches til selektivt at eliminere celleterapier in vivo; vævsspecifikke promotorer; UltraCAR-T-platformen til behandling af kræft; AdenoVerse Immunotherapy, et bibliotek af proprietære adenovektorer til genoverførsel; og ActoBiotics-platformen, genetisk modificerede bakterier, der leverer proteiner og peptider på slimhindesteder. Precigen, Inc. har samarbejds- og licensaftaler med Alaunos Therapeutics, Inc.; Ares Trading S.A.; Oragenics, Inc.; Castle Creek Biosciences, Inc.; Intrexon Energy Partners, LLC; og Intrexon Energy Partners II, LLC. Virksomheden var tidligere kendt som Intrexon Corporation og skiftede navn til Precigen, Inc. i januar 2020. Precigen, Inc. blev grundlagt i 1998 og har hovedkontor i Germantown, Maryland.
| Navn | Precigen |
| CEO | Helen Sabzevari |
| Hjemsted | Germantown,
md USA |
| Websted | |
| Sektor | Sundhed |
| Branche | Bioteknologi |
| Børsnotering | 08.08.2013 |
| Medarbejdere | 160 |
Tickersymboler
| Børs | Symbol |
|---|---|
NASDAQ | PGEN |
Frankfurt | I5X.F |
Düsseldorf | I5X.DU |
SIX | I5X.SW |
München | I5X.MU |